Project Grant R01CA299133
Award Date 8/24/26
Completion Date 7/31/31
Dollars Obligated $638K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Cancer Institute awarded The Leland Stanford Junior University $626,743 on July 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop intraoperative molecular imaging of lung cancer using panitumumab-IRDYE800 (PAN800). The funded research addresses accurate tumor localization during lung cancer surgery, particularly for small, less dense, or deep tumors and minimally invasive surgical approaches where palpation is difficult. Current techniques...
- The National Cancer Institute awarded The Washington University $532,127 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate the therapeutic index of TIP1-targeted beta and alpha radioimmunotherapy for non-small cell lung cancer treatment. The project develops and compares radiolabeled TIP1-targeted antibodies conjugated with alpha- and beta-emitting radionuclides to selectively deliver radiation to NSCLC tumor cells while minimizing off-target toxicity to...
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Cancer Institute awarded Matrisome Bio, Inc. $3,481,203 on September 23, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer. Matrisome Bio is developing molecularly targeted drugs based on nanobodies that specifically target disease-associated extracellular matrix (ECM) proteins highly expressed in lung cancer and other cancer indications while minimally expressed in...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...
- The National Cancer Institute awarded Senticell LLC $399,995 for a Phase I Small Business Technology Transfer (STTR) project grant on September 1, 2026, to develop an red blood cell–based liquid biopsy platform for detecting circulating tumor DNA in early-stage non-small cell lung cancer. The recipient will establish the biological and clinical performance of RBC-bound tumor DNA detection using vertebrate animal models of KRAS- and EGFR-driven lung cancer to characterize in vivo kinetics of...
- The National Institutes of Health National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $433,256 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify new protein targets and chemical leads that address epithelial-to-mesenchymal transition (EMT)–mediated resistance in EGFR-mutant lung cancer. The project applies fragment-based drug discovery to probe previously inaccessible binding sites and expand the biological...
- The National Cancer Institute awarded The University of Iowa $628,280 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to develop and evaluate targeted alpha particle therapy for pulmonary neuroendocrine tumors and carcinomas that have developed resistance to standard chemotherapy and radioligand therapy. The research targets CXCR4 (C-X-C chemokine receptor 4), highly expressed in these lung tumors, using 212Pb-pentixather as an alpha particle therapeutic agent....
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $708,377 on August 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a research project examining access to and clinical outcomes of radioligand therapy for prostate cancer in the U.S. veteran population. The award funds an analysis of lutetium Lu-177 vipivotide tetraxetan (LU-177), an FDA-approved radioligand therapy for castration-resistant prostate cancer. The research...